how make crypto coin Top Knowledge

The Japanese yen faces new risks. Strategists worry that the Bank of Japan may wait until March or later to raise interest rates. A new risk is emerging for the Japanese yen. Foreign exchange strategists in Tokyo warn that the Bank of Japan may wait until March or later next year to raise interest rates. On Wednesday, the market tasted this danger, and the yen fell to its lowest level in more than two weeks as traders responded to a Bloomberg report that the Bank of Japan is known to think that it is no harm to raise interest rates later. The yen only fell to 152.82 against the dollar, and the market is still debating whether the Bank of Japan will take action at its next meeting on December 19 or about a month later. Shusuke Yamada, head of Japan's foreign exchange and interest rate strategy at Bank of America in Tokyo, said that if policymakers put off raising interest rates for a longer time, the situation would be very different. "If the interest rate hike is postponed until March, the yen carry trade is likely to make a comeback," Yamada said on Thursday. "The yen is likely to fall again to a level just below the 157 mark hit in 155 or November."Xinxuan Group: The sales volume of the "Xin Huo Plan" is nearly 2 billion yuan, and Xinxuan Group disclosed the sales data of the live broadcast of the "Xin Huo Plan" in Shanxi Station. Statistics show that the two live broadcasts brought a total of 3.67 million orders, helping Shanxi specialty products with sales exceeding 180 million yuan to go nationwide. It is understood that this activity is guided by the Shanxi Provincial Department of Commerce. According to the disclosure, Xinxuan Group's "Xin Huo Plan" went to the whole country to carry out a number of live broadcast activities to help farmers, with sales of nearly 2 billion yuan. In addition, Xinxuan Group has donated a total of nearly 400 million yuan to the society. (Sina Technology)China Merchants Securities: Hisense's household appliances are obviously underestimated, and the safety cushion is thick, and it is rated as "strongly recommended". China Merchants Securities Research Report pointed out that the growth rate of Hisense's household appliances (000921.SZ) slowed down, showing the first year-on-year decline in nine quarters since 22Q3, and the market confidence was weak. The company is obviously underestimated, and the safety mat is thick. Looking horizontally, in 2025, the valuations of Hisense, Midea and Haier will be 10/13/13 times; Historically, the company's share price has been deeply adjusted since May this year, and the current valuation is at a lower level since the 22-year reform. Referring to the global valuation system, the steady-state PE hub of johnson controls/Carrier/Trane is 30/25/20 times, which is higher than the valuation of white power enterprises represented by Whirlpool and Electrolux. Hisense household appliances, as the standard of A-share central air conditioning, should enjoy a higher valuation than white power companies. The improvement of the company's bottom management promotes efficiency and cost reduction+the global operation competitiveness is constantly strengthened+the company's leading position is stable under the background of domestic substitution of central air conditioning, and it continues to be firmly optimistic about the company. It is estimated that the company's revenue will increase by +8%, +9% and +10% from 2024 to 2026, and its performance will increase by +15%, +14% and +16% respectively. Give a "strongly recommended" rating.

The Bank of Japan's short-term survey may show that business confidence has hardly changed. It is reported that the short-term survey released by the Bank of Japan on Friday may show that the mood of large manufacturers has remained almost unchanged in the last quarter under the influence of complex signals such as the recovery of the automobile industry and concerns about the global economic slowdown. Economists surveyed by data provider Quick predict that the prosperity judgment index of large-scale manufacturing industry will be +12, compared with +13 in the last survey. The survey is closely watched for clues about the decision of the Bank of Japan at its meeting next week. If it shows strong capital expenditure plan, high inflation expectation and tight employment situation, it may support the idea of raising interest rates early.In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for the replacement of generic drugs. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)Huaxin Securities: China Unicom's operating income grew steadily and maintained its "buy" rating. Huaxin Securities Research Report pointed out that since the beginning of this year, China Unicom (600050.SH) has seen steady growth in operating income, rapid improvement in profitability, steady expansion of user scale and continuous consolidation of network foundation, laying a more solid foundation for high-quality development of enterprises. Communication and digital intelligence services are driven by two wheels, injecting vitality into the company's performance. Looking forward to the whole year, the company will adhere to the general tone of steady progress, promote the network to be new, technology to be new and service to be new, strive to achieve the performance goal of steady growth of operating income and double-digit growth of profits throughout the year, take greater steps in high-quality development, and accelerate the construction of a world-class science and technology service enterprise with global competitiveness. With the gradual expansion of user scale and the drive of digital transformation, the company will benefit from the continuous improvement of revenue and profit and maintain the "buy" investment rating.

There are 695 listed companies in Jiangsu Province. According to the latest statistics of Jiangsu Listed Companies Association, there were 695 listed companies in Jiangsu Province by the end of November, including 15 new companies this year. Among the 695 companies, there are 216 main boards of Shanghai Stock Exchange, 110 in science and technology innovation board, 126 main boards of Shenzhen Stock Exchange (including one pure B-share), 196 Growth Enterprise Market and 47 North Stock Exchange. By geographical distribution, the total number of listed companies in Suzhou is far ahead in the province, reaching 219, 124 in Nanjing, 123 in Wuxi and 72 in Changzhou. In terms of A-shares, as of the end of November, there were 694 A-share listed companies in Jiangsu Province with a total market value of 6,745.231 billion yuan, accounting for 12.92% and 7.80% of the corresponding total of A-share listed companies respectively.South Korea's National Election Commission: South Korean President Yin Xiyue's remarks undermined South Korea's electoral system.Huadong Pharmaceutical has established a new company in Jiaxing with a registered capital of 60 million yuan. According to Tianyancha App, Huadong Pharmaceutical (Jiaxing) Co., Ltd. was recently established with Zhu Li as its legal representative and a registered capital of 60 million yuan. Its business scope includes drug wholesale, drug retail, decoction service for Chinese herbal pieces, third-class medical device operation, drug Internet information service, drug import and export, third-class medical device rental and medical device Internet information service. According to shareholder information, the company is wholly owned by Huadong Pharmaceutical (000963).